The total return over the past 12 months is -6.60% vs. +16.94% for the S&P 500. So far it's up -13.63% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (6.60%) | +58.61% | +49.95% | N/A | N/A | N/A |
| Total Return CAGR | (6.60%) | +58.61% | +49.95% | N/A | N/A | N/A |
| Revenue CAGR | +53.51% | +76.30% | +278.53% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Rhythm Pharmaceuticals, Inc. (RYTM)
| Year | Start price | End price | RYTM Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $107.04 | $92.45 | (13.63%) | +14.51% | (28.14%) |
| 2025 | $55.98 | $107.04 | +91.21% | +17.72% | +73.49% |
| 2024 | $45.97 | $55.98 | +21.78% | +24.89% | (3.11%) |
| 2023 | $29.12 | $45.97 | +57.86% | +26.19% | +31.67% |
| 2022 | $9.98 | $29.12 | +191.78% | (18.17%) | +209.95% |
| 2021 | $29.73 | $9.98 | (66.43%) | +28.74% | (95.17%) |
| 2020 | $22.96 | $29.73 | +29.49% | +18.37% | +11.12% |
| 2019 | $26.88 | $22.96 | (14.58%) | +31.22% | (45.80%) |
| 2018 | $29.06 | $26.88 | (7.50%) | (4.56%) | (2.94%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
